PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
Active, not recruiting · Phase 1, Phase 2 · NCT06153966
Conditions: Prion Disease
At a glance
- Research payments reported, 2025
- $125,260
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 85
About the trial
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Tested
- ION717 (drug), Placebo (drug)
- Dates
- Started 2024-01-04; completion 2030-08
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
From ClinicalTrials.gov, last updated 2026-09-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ionis Pharmaceuticals, Inc. reported $125,260 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Susan L. Perlman, MD Neurology · Los Angeles, CA
- Thomas Wisniewski, M.D. Neurology · New York, NY
- Brian S. Appleby, M.D. Psychiatry · Cleveland, OH
- Steven E. Arnold, MD Psychiatry · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Uh Cleveland Medical Center, OH $48,921
- Massachusetts General Hospital, MA $35,737
- The Regents of the University of California $21,464
- New York University School of Medicine $19,138
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.